Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Starlight: Fezolinetant dose finding in Japanese women with VMS
NCT05034042Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Nov 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fezolinetant in vasomotor symptoms (3 arms), sponsored by Astellas Pharma. Primary endpoint: Mean change from baseline in the frequency of mild, moderate and severe vasomotor symptom (VMS) at 8 weeks. Started Nov 2021; status: completed.
02
Drugs
fezolinetant
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT05034042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05034042.